Current through all regulations passed and filed through September 16, 2024
The diseases listed in this rule and classified as class
"A,"class "B," and class "C" are declared to be dangerous to the public health
and are reportable. The occurrence of cases or suspected cases of a disease
classified as class "A," class "B," or class "C" shall be reported, in detail,
by health care providers and laboratories to the board of health on forms as
prescribed and provided by the director and shall be reported in accordance
with this rule and Chapter 3701-3 of the Administrative Code.
(A) Due to the severity of disease or the
potential for epidemic spread, diseases of major public health concern are
classified as class "A." The following diseases are classified as class "A" and
shall be reported immediately via telephone in accordance with rules 3701-3-03,
3701-3-04, and
3701-3-05 of the Administrative
Code:
(1) Anthrax;
(2) Botulism, foodborne;
(3) Cholera;
(4) Diphtheria;
(5) Influenza "A" - novel virus
infection;
(6) Measles;
(7) Meningococcal disease;
(8) Middle east respiratory syndrome
(MERS);
(9) Plague;
(10) Rabies, human;
(11) Rubella (not congenital);
(12) Severe acute respiratory syndrome
(SARS);
(13) Smallpox;
(14) Tularemia;
(15) Viral hemorrhagic fever (VHF), including
Ebola virus disease, Lassa fever,Marburg hemorrhagic fever, and Crimean-Congo
hemorrhagic fever; and
(16) Any unexpected
pattern of cases, suspected cases, deaths or increased incidence of any other
disease of major public health concern, because of the severity of disease or
potential for epidemic spread, which may indicate a newly recognized infectious
agent, outbreak, epidemic, related public health hazard or act of
bioterrorism.
(B) Due to
the potential for epidemic spread, diseases of significant public health
concern are classified as class "B." The following diseases are classified as
class "B" and shall be reported in accordance with this rule and rules
3701-3-03, 3701-3-04, and
3701-3-05 of the Administrative
Code:
(1) Amebiasis;
(2) Arboviral neuroinvasive and
non-neuroinvasive diseases:
(a) Chikungunya
virus infection;
(b) Eastern equine
encephalitis virus disease;
(c)
LaCrosse virus disease (other California serogroup virus disease);
(d) Powassan virus disease;
(e) St. Louis encephalitis virus
disease;
(f) West Nile virus
infection;
(g) Western equine
encephalitis virus disease;
(h)
Yellow Fever;
(i) Zika virus
infection;
(j) Other Arthopod-borne diseases;
(3) Babesiosis;
(4) Botulism;
(a) Infant;
(b) Wound;
(5) Brucellosis;
(6) Campylobacteriosis;
(7)
Candida
auris;
(8) Carbapenemase-producing carbapenem-resistant
Enterobacteriaceae (CP-CRE):
(a) CP-CRE
Enterobacter spp.;
(b) CP-CRE
Escherichia coli;
(c) CP-CRE
Klebsiella spp.;
(d) CP-CRE
other;
(9)
Chancroid;
(10) Chlamydia trachomatis infections;
(11)
Coccidioidomycosis;
(12) Creutzfeldt-Jakob disease (CJD);
(13)
Cryptosporidiosis;
(14) Cyclosporiasis;
(15)
Dengue;
(16) E. coli O157:H7 and Shiga toxin-producing E. coli
(STEC);
(17) Ehrlichiosis/anaplasmosis;
(18)
Giardiasis;
(19) Gonorrhea (Neisseria gonorrhoeae);
(20)
Haemophilus influenzae (invasive disease);
(21)
Hantavirus;
(22) Hemolytic uremic syndrome (HUS);
(23)
Hepatitis A;
(24) Hepatitis B (non-perinatal);
(25)
Hepatitis B (perinatal);
(26) Hepatitis C
(non-perinatal);
(27) Hepatitis C (perinatal);
(28)
Hepatitis D (delta hepatitis);
(29) Hepatitis
E;
(30) Influenza-associated hospitalization;
(31)
Influenza-associated pediatric mortality;
(32) Legionnaires'
disease;
(33) Leprosy (Hansen disease);
(34)
Leptospirosis;
(35) Listeriosis;
(36) Lyme
disease;
(37) Malaria;
(38) Meningitis:
(a) Aseptic (viral);
(b) Bacterial;
(39)
Mumps;
(40) Pertussis;
(41) Poliomyelitis (including vaccine-associated
cases);
(42) Psittacosis;
(43) Q
fever;
(44) Rubella (congenital);
(45)
Salmonella
Paratyphi infection;
(46)
Salmonella Typhi infection (typhoid
fever);
(47) Salmonellosis;
(48)
Shigellosis;
(49) Spotted Fever Rickettsiosis, including Rocky
Mountain spotted fever (RMSF);
(50) Staphylococcus
aureus, with resistance or intermediate resistance to vancomycin (VRSA,
VISA);
(51) Streptococcal disease, group A, invasive
(IGAS);
(52) Streptococcal disease, group B, in
newborn;
(53) Streptococcal toxic shock syndrome
(STSS);
(54) Streptococcus pneumoniae, invasive disease
(ISP);
(55) Syphilis;
(56)
Tetanus;
(57) Toxic shock syndrome (TSS);
(58)
Trichinellosis;
(59) Tuberculosis (TB), including multi-drug resistant
tuberculosis (MDR-TB);
(60) Varicella;
(61) Vibriosis; and
(62)
Yersiniosis.
(C) The
following are classified as class "C" and shall be reported by the end of the
next business day in accordance with this rule and rules 3701-3-03, 3701-3-04,
and 3701-3-05 of the Administrative
Code unless paragraph (C)(7) of this rule applies - outbreak, unusual
incidence, or epidemic of other infectious diseases from the following sources:
(1) Community;
(2) Foodborne;
(3) Healthcare-associated;
(4) Institutional;
(5) Waterborne; and
(6) Zoonotic;
(7) If the outbreak, unusual incidence, or
epidemic, including but not limited to, histoplasmosis, pediculosis, scabies,
and staphylococcal infections, has an unexpected pattern of cases, suspected
cases, deaths, or increased incidence of disease that is of a major public
health concern pursuant to paragraph (A)(16) of this rule, then such outbreak,
unusual incidence, or epidemic shall be reported in accordance with paragraph
(A) of rule
3701-3-05 of the Administrative
Code.
